WhatsApp Group Join Now
Telegram Group Join Now

Lilly Zepbound drug (Weigh Loss) Is Prices in Half Now But there’s Catch

Lilly expands US supply of Zepbound by Inventing single-dose vials for weight loss. Which Will Help US Citizen

Lilly Told that 86% of Insurance health plans pay for medications that treat obesity. A month’s supply of Zepbound may otherwise require patients who are not eligible for weight reduction coverage, such as those enrolled in the Medicare health plan for senior citizens in the United States, to spend more than $1,000 out of pocket.

Eli Lilly said that single-dose vials of its well-known weight-loss medication Zepbound are now available for purchase in the United States. These vials are intended for patients whose health insurance coverage do not cover the full cost of the medication.

The two lowest doses of Zepbound, 2.5 mg and 5 mg vials, will be offered at Very Low costs of $399 and $549 for a month’s supply, respectively, on the drugmaker’s website LillyDirect, according to the company.

The U.S. FDA has labeled Zepbound and Novo’s Wegovy as being in short supply for the most of this year, indicating that Lilly and its Danish competitor Novo Nordisk are having difficulty producing enough of their obesity drugs to meet the rising demand.

Though it is no longer on the shortage list, the Food and Drug Administration now lists all dosages of Lilly’s Zepbound, also known chemically as tirzepatide, as available. Wegovy’s lowest dosage is nevertheless noted as being scarce.

In an interview, Lilly’s president of cardiometabolic health, Patrik Jonsson, stated that the introduction of these vials will greatly boost Zepbound’s availability in the United States.

See also  Are Bribes and Favors Hurting How Companies Hire People | Healthcare, Pharma

He added that a significant portion of patients do not proceed to greater doses of Zepbound than 5 mg during treatment. “We are very confident with both the auto-injectors and the vials that we will be able to supply the needs in the U.S. marketplace,” he said.

Lilly continued by stating that these vials’ pricing were 50% less than those of any other obesity medications in the GLP-1 family. According to earlier reports, individuals who are not eligible for Zepbound can get the medication in a pen from LillyDirect for as little as $550.

Lilly estimates that 86% of commercial health plans pay for medications that treat obesity. A month’s supply of Zepbound may otherwise require patients who are not eligible for weight reduction coverage, such as those enrolled in the Medicare health plan for senior citizens in the United States, to spend more than $1,000 out of pocket.

According to Jonsson, Lilly has already introduced vials of its tirzepatide medicines in Poland, Australia, and Canada.

Earlier this month, the business upped its revenue projection for the year by $3 billion due to increased supply and manufacturing capacity of Zepbound and the tirzepatide-based diabetes medication Mounjaro.

Working As Reporter on Pharmabharat.com And Part of Biocon Pharmaceuticals Team. Love To Give Updates On Stocks, News, Jobs, Internships, Scholarships

Leave a Comment